Market brief
European Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
European drug discovery services in 2026 concentrate at a small number of full-service CROs plus a specialised tools + platform layer. The directory surfaces 21 operators. Evotec (Hamburg, Germany) is the largest pan-European integrated drug-discovery CRO by directory scope, covering discovery + preclinical + early development services for sponsors across target identification, lead optimisation, and in-vivo pharmacology. Selvita (Kraków, Poland) anchors the CEE drug-discovery layer with medicinal chemistry, biology, and DMPK services plus development-services capacity downstream. Charles River Laboratories Finland (Kuopio) provides the Finnish preclinical + toxicology hub for CEE and Nordic sponsors. Gubra (Hørsholm, Denmark) specialises in obesity / cardiometabolic CRO services. Admescope (Oulu, Finland) runs dedicated ADMET services. Around these CRO anchors, Switzerland adds Biognosys (proteomics tools), InSphero + SUN bioscience (3D tissue models), Epithelix (in-vitro airway models), and Myria Biosciences (discovery biotech). Poland adds Molecure, Ryvu Therapeutics, and Pikralida at clinical-stage discovery. Sweden adds Biotage (separation + purification tools), AstraZeneca Gothenburg R&D, and IDL Diagnostics. The Baltics add the Latvian Institute of Organic Synthesis (academic research) and Klaipeda University Health Research Centre.
Evotec (Hamburg) and Selvita (Kraków) are the two largest European pan-regional drug-discovery CROs the directory surfaces - Evotec covering integrated discovery + preclinical + early development at global scope, Selvita covering medicinal chemistry, biology, DMPK, and development services at CEE regional scope.
Charles River Laboratories Finland (Kuopio) is the directory’s Nordic preclinical + toxicology + early-development services operator, part of the global Charles River network. Admescope (Oulu) adds dedicated ADMET + in-vitro drug metabolism services alongside Paras Biopharmaceuticals and Pharmatory in the Oulu cluster.
Denmark hosts Gubra (Hørsholm, obesity + cardiometabolic CRO services at clinical-stage scope) and the BioInnovation Institute (Copenhagen, translational research + discovery incubator), plus Visiopharm (digital pathology) and Evosep (sample preparation tools).
The Swiss discovery-tools cluster at Schlieren, Lausanne, and Plan-les-Ouates provides 3D tissue models (InSphero, SUN bioscience), in-vitro airway models (Epithelix), and proteomics tools (Biognosys) - complementary to the CRO layer rather than overlapping.
First-pass shortlist
Start with the scientific work package, not “drug discovery”
An integrated discovery campaign, a medicinal-chemistry programme, an ADMET package, and a 3D tissue experiment are different procurements. These routes reflect publicly described scope only; confirm the exact model, assay, data package, timeline, and programme acceptance directly with the operator.
Integrated discovery programmeTarget-to-candidate or discovery-to-early-development work
Hamburg, Germany
- Publicly stated scope
- Start with Evotec when the work needs a broad, integrated discovery and preclinical discussion across several disciplines rather than a single assay or specialist service.
- Confirm first
- Target and modality, desired work packages, in-house versus outsourced responsibilities, medicinal chemistry and biology needs, in-vivo or DMPK scope, data ownership, governance, and the relevant therapeutic-area team.
- Do not assume
- That an integrated service description confirms availability, a therapeutic-area fit, or that every stage will be conducted by one team or site.
Medicinal chemistry with biology and DMPKA CEE-based discovery-services route
Kraków, Poland
- Publicly stated scope
- Start with Selvita for its publicly described medicinal chemistry, biology, DMPK, and downstream development-services scope when those functions need to be linked in one discovery programme.
- Confirm first
- Chemistry series and target, FTE or project model, assay transfer, DMPK and bioanalysis needs, compound-management process, IP and data package, and downstream development requirements.
- Do not assume
- That a listed capability proves available chemistry capacity, a validated assay transfer, or clinical-development work for the same programme.
Preclinical pharmacology or toxicologyDefined in-vivo and translational-study support
Kuopio, Finland
- Publicly stated scope
- Start with Charles River Laboratories Finland where the programme needs a publicly described preclinical, toxicology, imaging, or translational-research discussion, then define the specific study route.
- Confirm first
- Species, disease model, endpoints, study type, GLP or non-GLP expectation, imaging or biomarker requirements, sample handling, report format, and regulatory use of the data.
- Do not assume
- That preclinical or toxicology wording confirms the needed model, regulatory-study acceptance, or a particular programme timeline.
ADMET or specialist disease scienceDrug metabolism, cardiometabolic models, or fibrosis work
Oulu, Finland; Hørsholm, Denmark; Umeå, Sweden
- Publicly stated scope
- Route by the narrow science: Admescope for ADMET and DMPK, Gubra for publicly described metabolic-disease models, or InfiCure Bio for fibrosis and chronic-inflammation models.
- Confirm first
- Assay or model specification, species and endpoints, validation and reproducibility expectations, bioanalytical handoff, comparable prior programmes, data deliverables, and decision criteria.
- Do not assume
- That a disease-area label makes a model suitable for the target, indication, or candidate without a study-specific scientific review.
Proteomics, organoids, or airway modelsA focused discovery-platform layer
Schlieren, Lausanne, and Plan-les-Ouates, Switzerland
- Publicly stated scope
- Start with Biognosys for proteomics readouts, InSphero or SUN bioscience for 3D tissue and organoid work, or Epithelix for publicly described in-vitro human airway models and inhaled-drug workflows.
- Confirm first
- Required model or sample type, biological relevance, assay validation, throughput, controls, endpoint and data-analysis plan, reproducibility, and how the result will change the next programme decision.
- Do not assume
- That an advanced model or proteomics platform replaces conventional preclinical evidence or validates a therapeutic hypothesis on its own.
Analysis
The European drug-discovery CRO core: Evotec, Selvita, Charles River
Three operators dominate the European drug-discovery CRO count in the directory. Evotec (Hamburg, Germany) is the largest pan-European integrated drug-discovery CRO the directory surfaces - covering target identification, hit discovery, lead optimisation, medicinal chemistry, in-vivo pharmacology, DMPK, and early clinical development at global scope with listed commercial scale. Selvita (Kraków, Poland) is the CEE drug-discovery anchor with medicinal chemistry, biology, and DMPK services plus development-services capacity downstream. Charles River Laboratories Finland (Kuopio) provides European preclinical toxicology + early-development services as part of the global Charles River network. Together these three cover full-service discovery + preclinical needs for most European sponsor programmes. For medicinal-chemistry-heavy work, Selvita is the CEE-based directory option. For integrated end-to-end discovery, Evotec is the directory’s largest full-service European option. For preclinical toxicology + regulatory-study support, Charles River Finland is the Nordic entry to the global Charles River network.
Analysis
ADMET and DMPK specialists
ADMET (absorption, distribution, metabolism, excretion, toxicity) and DMPK services are a distinct European specialism the directory surfaces. Admescope (Oulu, Finland) runs a dedicated ADMET + in-vitro drug metabolism CRO service - one of the few directory operators focused exclusively on the ADMET axis. Evotec and Selvita both run DMPK as part of their full-service stacks. Around Oulu, Paras Biopharmaceuticals and Pharmatory provide chemistry + CDMO services adjacent to the ADMET layer. For sponsors running discovery-to-preclinical programmes that need deep ADMET characterisation, Admescope is the specialist option; Evotec or Selvita is the choice when ADMET is bundled into a larger discovery programme.
Analysis
Swiss discovery tools + 3D-tissue cluster
Switzerland hosts a specialised discovery-tools cluster that the European drug-discovery ecosystem relies on. Biognosys (Schlieren) runs mass-spectrometry-based proteomics services for target identification and pharmacodynamic biomarker workflows. InSphero (Schlieren) and SUN bioscience (Lausanne) operate 3D tissue model + organoid assay services used by sponsors running target validation and early-efficacy workflows. Epithelix (Plan-les-Ouates) runs in-vitro human airway models (MucilAir) used in respiratory + inhaled drug programmes. Myria Biosciences (Basel) adds an early-stage discovery biotech operating in the Basel cluster. For sponsors running discovery programmes that depend on proteomics readouts, 3D tissue models, or inhaled-drug screening, these are the Swiss operators the directory surfaces.
Analysis
Polish + CEE discovery depth: Selvita, Ryvu, Molecure, Pikralida
Poland is the largest CEE drug-discovery geography by directory count. Selvita (Kraków) is the CRO anchor. Ryvu Therapeutics (Kraków) runs an in-house oncology pipeline using discovery infrastructure historically shared with Selvita. Molecure (Warsaw) operates small-molecule drug discovery with mRNA-target focus at clinical stage. Pikralida (Poznań) develops therapeutics at early-clinical stage. The Jagiellonian Centre of Innovation in Kraków provides life-science park infrastructure around the Jagiellonian University Medical College. For sponsors looking at CEE drug-discovery partnerships - Selvita for CRO services, Ryvu for in-house pipeline collaboration, Molecure for mRNA-target partnerships - Poland holds the highest CEE operator count the directory surfaces.
Analysis
Nordic + Baltic + German research layer
The European drug-discovery layer is anchored to an academic + translational-research infrastructure. AstraZeneca Gothenburg is the largest directory-listed Swedish pharma R&D site, with in-house discovery covering cardiovascular, renal, metabolic, oncology, respiratory, immunology, and neuroscience. The BioInnovation Institute (Copenhagen) runs as a translational-research incubator with early-stage biotech programmes. The Latvian Institute of Organic Synthesis (Riga) runs academic + applied chemistry research adjacent to the Polish Kraków discovery hub. Klaipeda University Health Research and Innovation Science Centre adds Lithuanian translational infrastructure. Germany’s broader research layer (EMBL Heidelberg, DKFZ, Max Delbrück Center Berlin) is covered in the German Biotech Landscape 2026 brief. For sponsors partnering on translational or early-discovery programmes, these academic and semi-academic operators are the discovery-adjacent reference points.
Analysis
Tools, purification, and sample-preparation
Drug discovery workflows depend on a tools + consumables + analytical-instruments layer the directory surfaces. Biotage (Uppsala, Sweden) runs separation, purification, and scavenger/reagent tools used across medicinal chemistry workflows. Evosep (Odense, Denmark) runs proteomics sample-preparation instruments (the Evosep One system). Biognosys (Schlieren, Switzerland) runs mass-spectrometry proteomics services. Combined with the pan-European reagent + consumables distribution through Thermo Fisher Supply (Vilnius, Warsaw) + Avantor/VWR (Darmstadt, Gdańsk), these operators form the discovery-adjacent supply layer - see the European Pharma Cold Chain & GDP Logistics 2026 brief for the distribution context.
Analysis
How to pick a European drug-discovery partner in 2026
Match the decision to the work. Full-service integrated discovery (target identification to early development): Evotec. CEE-based medicinal chemistry + biology + DMPK: Selvita. Preclinical toxicology + regulatory-study support: Charles River Laboratories Finland. Obesity / cardiometabolic specialist CRO: Gubra (Hørsholm). Dedicated ADMET + drug metabolism: Admescope (Oulu). Proteomics readouts + target ID: Biognosys. 3D tissue model + organoid screening: InSphero or SUN bioscience. In-vitro airway + inhaled drug: Epithelix. Translational + academic partnership: BioInnovation Institute Copenhagen or the Institute of Organic Synthesis (Latvia). Polish mRNA-target collaboration: Molecure. Polish in-house oncology-pipeline partnership: Ryvu Therapeutics. Separation + purification tools: Biotage. Proteomics sample-prep instruments: Evosep. The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.
